



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/600,816

06/20/2003

Gena S. Whitney

D0251 NP

5150

23914

7590

08/01/2006

LOUIS J. WILLE
BRISTOL-MYERS SQUIBB COMPANY
PATENT DEPARTMENT
P O BOX 4000
PRINCETON, NJ 08543-4000

EXAMINER

LI, RUIXIANG

ART UNIT

PAPER NUMBER

1646

DATE MAILED: 08/01/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/600,816	Applicant(s) WHITNEY ET AL.	
	Examiner Ruixiang Li	Art Unit 1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 May 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 35-44 is/are pending in the application.
- 4a) Of the above claim(s) 37 and 39-44 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 35,36 and 38 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 30 June 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>5/22/06, 7/1/05, 1/22/04,</u> | 6) <input checked="" type="checkbox"/> Other: <u>Sequence alignment.</u> |

DETAILED ACTION

Election/Restrictions

1. Applicant's election without traverse of Group II, claim 38, drawn to a method of diagnosing the presence of breast tumor comprising measuring RNA that encodes the polypeptide of SEQ ID NO: 3, in the reply filed on 05/22/2006 is acknowledged. Claims 35 and 36 are treated as linking claims. Claims 37, and 39-44 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Information Disclosure Statement

2. The information disclosure statements filed on 05/22/2006, 07/01/2005, and 01/22/2004 have been considered by the Examiner and a signed copy of form PTO-1449 is attached to the office action.

Drawings

3. The drawings filed on 06/03/2003 are accepted by the Examiner.

Objection to Title

4. The title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed.

Claim Rejections—35 USC § 112, 1st paragraph

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 35, 36, and 38 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of diagnosing breast cancer in a sample by determining the expression level of RNA encoding the polypeptide of SEQ ID NO: 3 comprising specific hybridizing between said RNA to the complementary sequence of SEQ ID NO: 2 or its coding sequence, does not reasonably provide enablement for the instantly claimed method comprising hybridizing between said RNA to the complementary sequence of a nucleic acid *comprising* a fragment of SEQ ID NO: 2, a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or a fragment thereof. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The factors that are considered when determining whether a disclosure satisfies enablement requirement include: (i) the quantity of experimentation necessary; (ii) the amount of direction or guidance presented; (iii) the existence of working examples; (iv) the nature of the invention; (v) the state of the prior art; (vi) the relative skill of those in the art; (vii) the predictability or unpredictability of the art; and (viii) the breadth of the claims. *Ex Parte Forman*, 230 USPQ 546 (Bd Pat. App. & Int. 1986); *In re Wands*, 858 F. 2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988).

The linking claims 35 and 36 are drawn to a method of diagnosing the presence of a tumor or predisposition to a tumor in a sample comprising the expression level of RNA encoding a polypeptide comprising the sequence of amino acids 2 to 357 of SEQ ID NO: 3 in a normal tissue sample and in a test tissue sample by measuring RNA of said polypeptide; and comparing said expression level of said polypeptide from said test tissue sample with said expression level of said polypeptide from said normal test sample; wherein an elevated expression level of said polypeptide in said test tissue sample relative to the expression level of said polypeptide in said normal sample is indicative of the presence of a tumor or a predisposition to a tumor. Claim 38 limits the tumor to be a breast tumor.

The claims are broad and are drawn to a method of diagnosing breast cancer using a genus of nucleic acids. While providing sufficient guidance and/or working examples on how to determine the expression level of mRNA encoding the polypeptide of SEQ ID NO: 3 in various normal tissues (Fig. 5) and tumor tissues (breast, stomach tumors, and testicular tumors) (see, e.g., Example 11, Fig. 16-18), using quantitative PCR analysis and specific primers and probe (page 213), the specification fails to provide sufficient guidance/direction or working examples on how to diagnose breast cancer by hybridizing mRNA in a breast tumor sample with a genus of nucleic acids, including a complementary sequence of a nucleic acid *comprising* a fragment of SEQ ID NO: 2, a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or a fragment thereof. Thus, use of a complementary sequence of these nucleic acids in the measurement of mRNA level by hybridization

may measure an mRNA that is distinct from the present mRNA. The state of the art is such that determining the specificity of hybridization is empirical by nature and the effect of mismatches is unpredictable, as taught by Wallace et al. (Methods Enzymol. 152:432-443, 1987) and Sambrook et al. (Molecular Cloning, A Laboratory Manual, 2nd Edition, 1989, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, page 11.47).

The prior art (see, e.g., U.S. Patent No. 6812339; U.S. Patent Application Publication No. 20030113798A1) teaches an isolated nucleic acid molecule that is 100% identical to SEQ ID NO: 2 and encodes a polypeptide that is 100% identical to SEQ ID NO: 3 of the present invention (see attached sequence alignment). Veiby et al. (U.S. Pub. No. US2003/0068636 A1, April 10, 2003; 102(e) date: 06/21/2001) teach a diagnostic method of assessing whether a patient is afflicted with breast cancer comprising determining the expression level of RNA encoding the polypeptide of SEQ ID NO: 2 (see sequence alignment). However, none of the prior art teaches diagnosing breast cancer by hybridizing mRNA in a breast tumor sample with a complementary sequence of a nucleic acid *comprising* a fragment of SEQ ID NO: 2, a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 3 or a fragment thereof.

While an artisan has a high level of skill in determining expression profile of an mRNA in normal tissues and tumor samples and diagnosing tumors, such as breast cancer, the recited use of a genus of nucleic acids in the claimed methods would

Art Unit: 1646

require an artisan to carry out undue experimentation to practice the claimed invention.

Accordingly, in view of the factors discussed above, it would require undue experimentation for one skilled in the art to use the invention commensurate in scope with these claims.

Claim Rejections 35 USC § 112, 2nd paragraph

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

8. Claims 35, 36, and 38 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 35 is indefinite because it, in part b), recites "said expression level of said polypeptide". It is clear from part a) of the claim that the expression level of RNA, not the expression level of polypeptide, is determined.

Claims 36 and 38 are rejected as dependent claims from claim 35.

Claim Rejections—35 USC § 102(e)

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent,

Art Unit: 1646

except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

10. Claims 35, 36, and 38 are rejected under 35 U.S.C. 102(e) as being anticipated by Veiby et al. (U.S. Pub. No. US2003/0068636 A1, April 10, 2003; 102(e) date: 06/21/2001).

Veiby et al. teach a nucleic acid marker (SEQ ID NO: 59) for breast cancer (see Table 2) that comprises the coding sequence of SEQ ID NO: 2 of the present invention and encodes a protein (SEQ ID NO: 60) that is 100% identical to the polypeptide of SEQ ID NO: 3 of the present invention (see attached sequence alignment). Veiby et al. teach a diagnostic method of assessing whether a patient is afflicted with breast cancer comprising determining the level of expression of a marker of the invention in a patient sample and the normal level of expression of the marker in a control non-cancerous breast sample. A significantly higher level of expression of the nucleic acid marker in the patient sample as compared to the normal level is an indication that the patient is afflicted with breast cancer ([0020] to [0023]). Veiby et al. further teach that expression of a nucleic acid marker can be assessed by preparing mRNA/cDNA from cells in a patient sample, and by hybridizing the mRNA/cDNA with a reference polynucleotide which is a complement of a marker nucleic acid, or a fragment thereof ([0122]). Thus, the teachings of Veiby et al. meet the limitations of claims 35, 36, and 38.

Conclusion

11. No claims are allowed.

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, can be reached on (571) 272-0835. The fax number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, please contact the Electronic Business Center (EBC) at the toll-free phone number 866-217-9197.

Ruixiang Li

Ruixiang Li, Ph.D.
Primary Examiner
July 29, 2006

RUIXIANG LI, PH.D.
PRIMARY EXAMINER

-continued

Val	Asp	Cys	Tyr	Val	Glu	Asp	Pro	Gln	Gly	Asn	Thr	Ile	Tyr	Arg	Glu
65					70					75					80
Thr	Lys	Lys	Gln	Tyr	Asp	Ser	Phe	Thr	Tyr	Arg	Ala	Glu	Val	Lys	Gly
			85						90					95	
Val	Tyr	Gln	Phe	Cys	Phe	Ser	Asn	Glu	Phe	Ser	Thr	Phe	Ser	His	Lys
		100						105						110	
Thr	Val	Tyr	Phe	Asp	Phe	Gln	Val	Gly	Asp	Glu	Pro	Pro	Ile	Leu	Pro
	115					120						125			
Asp	Met	Gly	Asn	Arg	Val	Thr	Ala	Leu	Thr	Gln	Met	Glu	Ser	Ala	Cys
	130					135						140			
Val	Thr	Ile	His	Glu	Ala	Leu	Lys	Thr	Val	Ile	Asp	Ser	Gln	Thr	His
	145			150						155					160
Tyr	Arg	Leu	Arg	Glu	Ala	Gln	Asp	Arg	Ala	Arg	Ala	Glu	Asp	Leu	Asn
			165					170						175	
Ser	Arg	Val	Ser	Tyr	Trp	Ser	Val	Gly	Glu	Thr	Ile	Ala	Leu	Phe	Val
		180						185						190	
Val	Ser	Phe	Ser	Gln	Val	Leu	Leu	Leu	Lys	Ser	Phe	Phe	Thr	Glu	Lys
		195				200						205			
Arg	Pro	Ile	Ser	Arg	Ala	Val	His	Ser							
	210					215									

<210> SEQ ID NO 59

<211> LENGTH: 2316

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 59

```

ccacgcgtcc ggtctccccc agcactgagg agctcgccctg ctgcctctctt gcgcgcggga      60
agcagcacca agttcacggc caacgccttg gcactagggt ccagaatggc tacaacagtc      120
cctgatgggt gccgcaatgg cctgaaatcc aagtactaca gactttgtga taaggctgaa      180
gcttggggga tcgtcctaga aacggtaggc acagccgggg ttgtgacctc ggtggccttc      240
atgctcactc tcccgatcct cgtctgcaag gtgcaggact ccaacaggcg aaaaatgctg      300
cctaactcagt ttctcttctc cctgggtgtg ttgggcacat ttggcctcac ctctgccttc      360
atcatcggac tggacgggag cacagggccc acacgcttct tcctcttttg gatcctcttt      420
tccatctgct tctcctgcct gctggctcat gctgtcagtc tgaccaagct cgtccggggg      480
aggaagcccc ttccctgttt ggtgattctg ggtetggccg tgggcttcag ctagtccag      540
gatgttatcg ctattgaata tattgtcctg accatgaata ggaccaacgt caatgtcttt      600
tctgagcttt ccgctcctcg tcgcaatgaa gactttgtcc tcctgctcac ctacgtcctc      660
ttcttgatgg cgctgacctt cctcatgtcc tccttcacct tctgtgggtc cttcacgggc      720
tggaagagac atggggccca catctacctc acgatgctcc tctccattgc catctgggtg      780
gcctggatca ccctgtcatc gcttctgtac tttagccgca ggtgggatga caccatcctc      840
agctccgcct tggctgccaa tggctgggtg ttccctgttg cttatgttag tcccagttt      900
tggctgctca caaagcaacg aaaccccatg gattatcctg ttgaggatgc tttctgtaaa      960
cctcaactcg tgaagaagag ctatggtgtg gagaacagag cctactctca agaggaaatc     1020
actcaagggt ttgaagagac aggggacacg ctctatgccc cctattccac acattttcag     1080
ctgcagaacc agcctcccca aaaggaatcc tccatccac gggccacgc ttggccgagc     1140

```

↓
-continued

```

ccttacaaag actatgaagt aaagaagag ggcagctaac tctgtcctga agagtgggac 1200
aaatgcagcc gggcggcaga tctagcggga gctcaaaggg atgtgggcga aatctgagtc 1260
ttctgagaaa actgtacaag acactacggg aacagtttgc ctccctccca gcctcaacca 1320
caattcttcc atgtctgggc tgatgtgggc tagtaagact ccagttctta gaggcgctgt 1380
agtatttttt tttttttgtc tcatcctttg gatacttctt ttaagtggga gtctcaggca 1440
actcaagttt agacccttac tctttttgtt tgttttttga aacaggatct tgctctgtca 1500
cccaggcttg agtgcagtg ggcgatcaca gccagtgca gcctcgacca cctgtgtctca 1560
agcaatctct ccattctccat ctcccaaggt gctgggatga caggcgtgag ccacagctcc 1620
cagcctaggc ccttaattct gctgttattt tccatggact aaaggtctgg tcacttgagc 1680
tcacgttgcc tcacacagct ctaggggcct gctcctctaa ctacacagtg gttttgtgag 1740
gctctgtggc ccagagcaga cctgcatact tgagcaaaaa tagcaaaagc ctctctcagc 1800
ccactggcct gaattctacac tggaagccaa cttgctggca cccccgctcc ccaacccttc 1860
ttgcctgggt aggagaggct aaagatcacc ctaaatttac tcactctctt agtctgcct 1920
cacattgggc ctacagagct cccagcacc aattcacagg tcacccctct ctctctgcac 1980
tgtcccaaaa cttgctgtca attccgagat ctaattctcc cctacgtctt gccaggaatt 2040
ctttcagacc tcactagcac aagcccgtt gctccttgct aggagaattt gtagatcatt 2100
ctcaactcaa attcctgggg ctgatacttc tctcatcttg caccacaacc tctgtaata 2160
gatttaccgc atttacggct gcattctgta agtgggcatg gtctcctaag ggaggagtgt 2220
tcattgtata ataagttatt cacctgagta tgcaataaag atgtgggtggc cactctttca 2280
tgggtgtggc agcaaaaaaa aaaaaaaaaa aaaaaa 2316

```

<210> SEQ ID NO 60
 <211> LENGTH: 357
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

See sequence alignment attached below.

<400> SEQUENCE: 60

```

Met Ala Thr Thr Val Pro Asp Gly Cys Arg Asn Gly Leu Lys Ser Lys
 1             5             10             15
Tyr Tyr Arg Leu Cys Asp Lys Ala Glu Ala Trp Gly Ile Val Leu Glu
 20            25            30
Thr Val Ala Thr Ala Gly Val Val Thr Ser Val Ala Phe Met Leu Thr
 35            40            45
Leu Pro Ile Leu Val Cys Lys Val Gln Asp Ser Asn Arg Arg Lys Met
 50            55            60
Leu Pro Thr Gln Phe Leu Phe Leu Leu Gly Val Leu Gly Ile Phe Gly
 65            70            75            80
Leu Thr Phe Ala Phe Ile Ile Gly Leu Asp Gly Ser Thr Gly Pro Thr
 85            90            95
Arg Phe Phe Leu Phe Gly Ile Leu Phe Ser Ile Cys Phe Ser Cys Leu
100           105           110
Leu Ala His Ala Val Ser Leu Thr Lys Leu Val Arg Gly Arg Lys Pro
115           120           125
Leu Ser Leu Leu Val Ile Leu Gly Leu Ala Val Gly Phe Ser Leu Val
130           135           140
Gln Asp Val Ile Ala Ile Glu Tyr Ile Val Leu Thr Met Asn Arg Thr

```

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM nucleic - nucleic search, using sw model

Run on: June 10, 2006, 15:07:32 ; Search time 430 Seconds
(without alignments)
10687.077 Million cell updates/sec

Title: US-10-600-816-2

Perfect score: 2456

Sequence: 1 ataacagcatgaagtcgcgt.....ggcagcaaaaaaaaaa 2456

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 1403666 seqs, 93554401 residues

Total number of hits satisfying chosen parameters: 2807332

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

Issued Patents NA:*

- 1: /EMC Celleria_SIDS3/ptodata/2/ina/1 COMB.seq:*
- 2: /EMC Celleria_SIDS3/ptodata/2/ina/5 COMB.seq:*
- 3: /EMC Celleria_SIDS3/ptodata/2/ina/6A COMB.seq:*
- 4: /EMC Celleria_SIDS3/ptodata/2/ina/6B COMB.seq:*
- 5: /EMC Celleria_SIDS3/ptodata/2/ina/7 COMB.seq:*
- 6: /EMC Celleria_SIDS3/ptodata/2/ina/H COMB.seq:*
- 7: /EMC Celleria_SIDS3/ptodata/2/ina/PCTUS COMB.seq:*
- 8: /EMC Celleria_SIDS3/ptodata/2/ina/PP COMB.seq:*
- 9: /EMC Celleria_SIDS3/ptodata/2/ina/RE COMB.seq:*
- 10: /EMC Celleria_SIDS3/ptodata/2/ina/backfiles.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	2456	100.0	2456	3	US-09-949-016-572
2	2289	93.2	2289	3	US-09-949-016-3613
3	1215.4	49.5	26086	3	US-09-949-016-15355
4	1215.4	49.5	26238	3	US-09-949-016-12314
5	1126	45.8	1212	3	US-09-188-930-249
6	1126	45.8	1212	3	US-09-312-283C-249
7	1031.6	42.0	1228	3	US-09-495-050A-223
8	600.6	24.5	601	3	US-09-949-016-29173
9	600.6	24.5	601	3	US-09-949-016-29174
10	600.6	24.5	601	3	US-09-949-016-126957
11	600.6	24.5	601	3	US-09-949-016-126958
12	418.6	17.0	601	3	US-09-949-016-29170
13	418.6	17.0	601	3	US-09-949-016-126954
14	292.2	11.9	311	3	US-09-188-930-4
15	292.2	11.9	311	3	US-09-312-283C-4
16	204.4	8.3	206	4	US-09-880-107-295
17	201.4	8.2	1880	3	US-09-620-312D-897
18	179.4	7.3	2799	3	US-09-495-050A-291
19	139.4	5.7	2484	3	US-09-276-531-46
20	117.8	4.8	389504	3	US-09-949-016-11774
21	116.8	4.8	87039	3	US-09-949-016-15691
22	115.6	4.7	75929	3	US-09-949-016-15543
23	115.6	4.7	75929	3	US-09-949-016-15544

c	24	115.2	4.7	31623	3	US-09-949-016-15945	Sequence 15945, A
c	25	115.2	4.7	93532	3	US-09-949-016-15944	Sequence 15944, A
	26	115	4.7	26769	3	US-09-949-016-14934	Sequence 14934, A
	27	115	4.7	46843	3	US-09-949-016-14194	Sequence 14194, A
	28	115	4.7	64610	3	US-09-949-016-12214	Sequence 12214, A
	29	114.8	4.7	601	3	US-09-949-016-47244	Sequence 47244, A
c	30	114.8	4.7	15265	3	US-09-949-016-13122	Sequence 13122, A
	31	114.4	4.7	601	3	US-09-949-016-47245	Sequence 47245, A
c	32	113.8	4.6	601	3	US-09-949-016-48485	Sequence 48485, A
	33	113.8	4.6	58768	3	US-09-949-016-13175	Sequence 13175, A
	34	113.2	4.6	47883	3	US-09-949-016-11866	Sequence 11866, A
	35	113.2	4.6	47883	3	US-09-949-016-17213	Sequence 17213, A
	36	112.6	4.6	37792	3	US-09-949-016-12503	Sequence 12503, A
	37	112.6	4.6	37795	3	US-09-949-016-14263	Sequence 14263, A
	38	112.4	4.6	21679	3	US-09-949-016-15250	Sequence 15250, A
c	39	112.4	4.6	285986	3	US-09-949-016-12287	Sequence 12287, A
c	40	112.4	4.6	288031	3	US-09-949-016-14864	Sequence 14864, A
c	41	112.2	4.6	601	3	US-09-949-016-88852	Sequence 88852, A
c	42	112.2	4.6	601	3	US-09-949-016-88853	Sequence 88853, A
	43	111.6	4.5	601	3	US-09-949-016-204419	Sequence 204419, A
	44	111.6	4.5	601	3	US-09-949-016-204420	Sequence 204420, A
	45	111.6	4.5	601	3	US-09-949-016-204489	Sequence 204489, A

ALIGNMENTS

RESULT 1

US-09-949-016-572
; Sequence 572, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949, 016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 572
; LENGTH: 2456
; TYPE: DNA
; ORGANISM: Human
; US-09-949-016-572

Query Match 100.0%; Score 2456; DB 3; Length 2456;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	ATAACAGCATGAAGTCCGCTGCGGAGTGGAACTGGATAGCGGTCTCTCCCTCGAGGGCGGCTTTATA	60
Db	1	ATAACAGCATGAAGTCCGCTGCGGAGTGGAACTGGATAGCGGTCTCTCCCTCGAGGGCGGCTTTATA	60
Qy	61	TCCTTGTCCCTCTGCTCACCCTCGCTCGTTCCTCCCTCGAGGGCGGCTTTATA	120
Db	61	TCCTTGTCCCTCTGCTCACCCTCGCTCGTTCCTCCCTCGAGGGCGGCTTTATA	120
Qy	121	ACAACATGCTCAGAGTCCGAGGGCGGAGTCTCCAAAGTCTCCCTCCAGACTGAGGAG	180
Db	121	ACAACATGCTCAGAGTCCGAGGGCGGAGTCTCCAAAGTCTCCCTCCAGACTGAGGAG	180
Qy	181	CTCGCTGTGCTCCCTTTTGGCGGGGAGGAGCAGCAGTTCACGGCCCAACGCTTGGC	240
Db	181	CTCGCTGTGCTCCCTTTTGGCGGGGAGGAGCAGCAGTTCACGGCCCAACGCTTGGC	240
Qy	241	ACTAGGGTCCAGAATGGCTACAACTGCTCCCTGATGTTGCCCAATGGCTGAATCCAA	300

[illegible]

Db	1321	CAGCTAACTCTGTCGAGAGTGGGGCAAAATCGAGCCGGGGCGCAGATCTACGGGGAGC	1381
Qy	1381	TCAAAGGAGTGTGGGCGAAATCTTGAGTCTTCTTGAGAAAACTGTACAAGACACTACGGGA	1440
Db	1381	TCAAAGGAGTGTGGGCGAAATCTTGAGTCTTCTTGAGAAAACTGTACAAGACACTACGGGA	1440
Qy	1441	ACAGTTGGCTCCTCCAGCCCTCAACCAAAATCTTCCAATGCTGGGGCTGATGTGGCT	1500
Db	1441	ACAGTTGGCTCCTCCAGCCCTCAACCAAAATCTTCCAATGCTGGGGCTGATGTGGCT	1500
Qy	1501	AGTAAGACTCCAGTCTTAGAGCGCTGTAGTAATTTTTTTTTTTTTTGTCTCATCTTTGG	1560
Db	1501	AGTAAGACTCCAGTCTTAGAGCGCTGTAGTAATTTTTTTTTTTTTTGTCTCATCTTTGG	1560
Qy	1561	ATACTCTTTTAAAGTGGGAGTCTCAGGCAACTCAAGTTTAGACCCCTACTCTCTTTTGT	1620
Db	1561	ATACTCTTTTAAAGTGGGAGTCTCAGGCAACTCAAGTTTAGACCCCTACTCTCTTTTGT	1620
Qy	1621	GTTTTTGAAACAGGATCTTGCTCTGTCAACCCAGGCTTGAGTCAGTGTGCGATCACAG	1680
Db	1621	GTTTTTGAAACAGGATCTTGCTCTGTCAACCCAGGCTTGAGTCAGTGTGCGATCACAG	1680
Qy	1681	CCAGTGCACCTCGACCACTGTGCTCAAGCAATCCTCCCATCTCCATCTCCCAAGTG	1740
Db	1681	CCAGTGCACCTCGACCACTGTGCTCAAGCAATCCTCCCATCTCCATCTCCCAAGTG	1740
Qy	1741	CTGGGATGACAGCGCTGAGCCACAGCTCCAGCGCTAGGCGCTTAATCTTGCTGTATTTT	1800
Db	1741	CTGGGATGACAGCGCTGAGCCACAGCTCCAGCGCTAGGCGCTTAATCTTGCTGTATTTT	1800
Qy	1801	CCATGGACTAAAGGTCTGGTCACTGAGCTCACGCTGGCTCACACAGCTCTAGGGGCTG	1860
Db	1801	CCATGGACTAAAGGTCTGGTCACTGAGCTCACGCTGGCTCACACAGCTCTAGGGGCTG	1860
Qy	1861	CTCCTCTAACTCACAGTGGTTTTGTGAGGCTCTGTGGCCAGAGCAGACTGCATATCT	1920
Db	1861	CTCCTCTAACTCACAGTGGTTTTGTGAGGCTCTGTGGCCAGAGCAGACTGCATATCT	1920
Qy	1921	GAGCAAAAAATAGCAAAAGGCTCTCTCAGGCCACTGGCTGAATCTACCTGGAAGCCAAC	1980
Db	1921	GAGCAAAAAATAGCAAAAGGCTCTCTCAGGCCACTGGCTGAATCTACCTGGAAGCCAAC	1980
Qy	1981	TTGCTGGCACCCTCGCTCCCAACCTTCTTGCTGGGTAGGAGGCTTAAGATCACCC	2040
Db	1981	TTGCTGGCACCCTCGCTCCCAACCTTCTTGCTGGGTAGGAGGCTTAAGATCACCC	2040
Qy	2041	TAAATTTACTCATCTCTAGTGTCTGCTCCATCTGGGCTCAGCAGCTCCCCAGACCA	2100
Db	2041	TAAATTTACTCATCTCTAGTGTCTGCTCCATCTGGGCTCAGCAGCTCCCCAGACCA	2100
Qy	2101	ATTCA CAGGTCACCCCTCTCTTTGCACTGTGCCCAAACTTGCTGTCTCAATTTCCGAGATC	2160
Db	2101	ATTCA CAGGTCACCCCTCTCTTTGCACTGTGCCCAAACTTGCTGTCTCAATTTCCGAGATC	2160
Qy	2161	TAAATCTCCCTTACGCTCTGCGAGGAATTTCTTTCAGACCTCACTAGCACAAAGCCGGTTG	2220
Db	2161	TAAATCTCCCTTACGCTCTGCGAGGAATTTCTTTCAGACCTCACTAGCACAAAGCCGGTTG	2220
Qy	2221	CTCCTTGT CAGGAGAAATTTGTAGATCATTTCTCAATTTCTCTGGGGCTGATCTCT	2280
Db	2221	CTCCTTGT CAGGAGAAATTTGTAGATCATTTCTCAATTTCTCTGGGGCTGATCTCT	2280
Qy	2281	CTCATCTTGGACCCCAACCTCTGTAAATAGATTTACCGCATTTACGGCTGCATCTGTAA	2340
Db	2281	CTCATCTTGGACCCCAACCTCTGTAAATAGATTTACCGCATTTACGGCTGCATCTGTAA	2340
Qy	2341	GTGGGCACTGGTCTCTCAATGAGGAGTGTTCATTTGTAATAAGTTATTTACCTGAGTAT	2400
Db	2341	GTGGGCACTGGTCTCTCAATGAGGAGTGTTCATTTGTAATAAGTTATTTACCTGAGTAT	2400
Qy	2401	GCAATTAAGATGTGGTGCCACTCTTTTCAATGTTGGTGCGACAAAAAATAAAAAA	2456
Db	2401	GCAATTAAGATGTGGTGCCACTCTTTTCAATGTTGGTGCGACAAAAAATAAAAAA	2456

301 SQEETQGFETGDTLYAPYSTHFLQNPQPKFSPRAHAWPSYKDYEVKKEGS 357

RESULT 2
US-10-225-567A-454
; Sequence 454, Application US/10225567A
; Publication No. US20030113798A1
; GENERAL INFORMATION:
; APPLICANT: LifeSpan Biosciences
; APPLICANT: Brown, Joseph P.
; APPLICANT: Burner, Glenna C.
; APPLICANT: Roush, Christine L.
; TITLE OF INVENTION: ANTIGENIC PEPTIDES AND ANTIBODIES FOR G PROTEIN-COUPLED RECEPTORS
; FILE REFERENCE: 1920-4-4
; CURRENT APPLICATION NUMBER: US/10/225,567A
; CURRENT FILING DATE: 2001-12-19
; PRIOR APPLICATION NUMBER: 60/257,144
; PRIOR FILING DATE: 2000-12-19
; NUMBER OF SEQ ID NOS: 2292
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 454
; LENGTH: 357
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-225-567A-454

Query Match 100.0%; Score 1865; DB 4; Length 357;
Best Local Similarity 100.0%; Pred. No. 2.7e-171;
Matches 357; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MATTPDGCGRGLSKYRLCDKAEAGIVLETAVATAGVVTSAFMTLPILVCKVQDSN 60
DB 1 MATTPDGCGRGLSKYRLCDKAEAGIVLETAVATAGVVTSAFMTLPILVCKVQDSN 60
QY 61 RRKMLPTQFLFGLVGLFGLTFAPIIGLDGSTGPTFRFLGILFISICFSCILAHAVSLT 120
DB 61 RRKMLPTQFLFGLVGLFGLTFAPIIGLDGSTGPTFRFLGILFISICFSCILAHAVSLT 120
QY 121 KLVGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEDFVLL 180
DB 121 KLVGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEDFVLL 180
QY 181 LTVLFLMALTFMLSSFTFCGSGTGWKRGHAIYLTMLLSIAIWAIVATITLMLPDFDRW 240
DB 181 LTVLFLMALTFMLSSFTFCGSGTGWKRGHAIYLTMLLSIAIWAIVATITLMLPDFDRW 240
QY 241 DDTILSSALAANGWVFLAYVSPFLLTKORNPMDYPVEDAFCKPQLVKKSYGVENRAY 300
DB 241 DDTILSSALAANGWVFLAYVSPFLLTKORNPMDYPVEDAFCKPQLVKKSYGVENRAY 300
QY 301 SQEETQGFETGDTLYAPYSTHFLQNPQPKFSPRAHAWPSYKDYEVKKEGS 357
DB 301 SQEETQGFETGDTLYAPYSTHFLQNPQPKFSPRAHAWPSYKDYEVKKEGS 357

RESULT 3
US-10-224-289-4
; Sequence 4, Application US/10224289
; Publication No. US20030207289A1
; GENERAL INFORMATION:
; APPLICANT: LEWIN, DAVID A.
; APPLICANT: STEWART, TIMOTHY A.
; TITLE OF INVENTION: GPCR-LIKE RETINOIC ACID-INDUCED GENE 1 PROTEIN AND
; TITLE OF INVENTION: NUCLEIC ACID
; FILE REFERENCE: 980081-0085
; CURRENT APPLICATION NUMBER: US/10/224,289
; CURRENT FILING DATE: 2002-08-20
; PRIOR APPLICATION NUMBER: 60/313,940
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4

LENGTH: 357
TYPE: PRT
ORGANISM: Homo sapiens
US-10-224-289-4
Query Match 100.0%; Score 1865; DB 4; Length 357;
Best Local Similarity 100.0%; Pred. No. 2.7e-171;
Matches 357; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MATTPDGCGRGLSKYRLCDKAEAGIVLETAVATAGVVTSAFMTLPILVCKVQDSN 60
DB 1 MATTPDGCGRGLSKYRLCDKAEAGIVLETAVATAGVVTSAFMTLPILVCKVQDSN 60
QY 61 RRKMLPTQFLFGLVGLFGLTFAPIIGLDGSTGPTFRFLGILFISICFSCILAHAVSLT 120
DB 61 RRKMLPTQFLFGLVGLFGLTFAPIIGLDGSTGPTFRFLGILFISICFSCILAHAVSLT 120
QY 121 KLVGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEDFVLL 180
DB 121 KLVGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEDFVLL 180
QY 181 LTVLFLMALTFMLSSFTFCGSGTGWKRGHAIYLTMLLSIAIWAIVATITLMLPDFDRW 240
DB 181 LTVLFLMALTFMLSSFTFCGSGTGWKRGHAIYLTMLLSIAIWAIVATITLMLPDFDRW 240
QY 241 DDTILSSALAANGWVFLAYVSPFLLTKORNPMDYPVEDAFCKPQLVKKSYGVENRAY 300
DB 241 DDTILSSALAANGWVFLAYVSPFLLTKORNPMDYPVEDAFCKPQLVKKSYGVENRAY 300
QY 301 SQEETQGFETGDTLYAPYSTHFLQNPQPKFSPRAHAWPSYKDYEVKKEGS 357
DB 301 SQEETQGFETGDTLYAPYSTHFLQNPQPKFSPRAHAWPSYKDYEVKKEGS 357

RESULT 4
US-10-295-027-620
; Sequence 620, Application US/10295027
; Publication No. US20030232350A1
; GENERAL INFORMATION:
; APPLICANT: Afar, Daniel
; APPLICANT: Aziz, Natasha
; APPLICANT: Ginsberg, Wendy M.
; APPLICANT: Gish, Kurt C.
; APPLICANT: Glynn, Richard
; APPLICANT: Hevezi, Peter A.
; APPLICANT: Mack, David H.
; APPLICANT: Murray, Richard
; APPLICANT: Watson, Susan R.
; APPLICANT: Eos Biotechnology, Inc.
; TITLE OF INVENTION: Methods of Diagnosis of Cancer, Compositions and
; TITLE OF INVENTION: Methods of Screening for Modulators of Cancer
; FILE REFERENCE: 018501-012500US
; CURRENT APPLICATION NUMBER: US/10/295,027
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: US 09/663,733
; PRIOR FILING DATE: 2000-09-15
; PRIOR APPLICATION NUMBER: US 60/350,666
; PRIOR FILING DATE: 2001-11-13
; PRIOR APPLICATION NUMBER: US 60/335,394
; PRIOR FILING DATE: 2001-11-15
; PRIOR APPLICATION NUMBER: US 60/332,464
; PRIOR FILING DATE: 2001-11-21
; PRIOR APPLICATION NUMBER: US 60/334,393
; PRIOR FILING DATE: 2001-11-29
; PRIOR APPLICATION NUMBER: US 60/340,376
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: US 60/347,211
; PRIOR FILING DATE: 2002-01-08
; PRIOR APPLICATION NUMBER: US 60/347,349
; PRIOR FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/355,250
; PRIOR FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US 60/356,714

Result No.	Score	Query Match	Length	DB	ID	Description
1	2456	100.0	2456	6	US-10-225-567A-453	Sequence 453, App
2	2456	100.0	2456	7	US-10-269-909-63	Sequence 63, Appl
3	2456	100.0	2456	7	US-10-269-909-64	Sequence 64, Appl
4	2456	100.0	2456	7	US-10-295-027-619	Sequence 619, App
5	2456	100.0	2456	8	US-10-600-816-2	Sequence 2, Appl
6	2456	100.0	2456	9	US-10-775-920-10	Sequence 10, Appl
7	2456	100.0	2456	10	US-10-936-626-40	Sequence 40, App
8	2456	100.0	2456	10	US-10-938-061-40	Sequence 40, App
9	2456	100.0	2456	16	US-11-165-041-32	Sequence 32, Appl
10	2448	99.7	2456	8	US-10-600-816-18	Sequence 18, Appl
11	2443	99.5	4239	6	US-10-198-846-10424	Sequence 10424, A
12	2439.8	99.3	2446	9	US-10-775-920-11	Sequence 11, Appl
13	2302	93.7	2302	7	US-10-224-283-3	Sequence 3, Appl
14	2302	93.7	2302	8	US-10-240-425-405	Sequence 405, App
15	2302	93.7	2302	9	US-10-775-920-9	Sequence 9, Appl
16	2302	93.7	2302	10	US-10-510-507-2	Sequence 2, Appl
17	2286	93.1	2316	6	US-10-176-847-59	Sequence 59, Appl

181	Db	 CTCGCTGCTGCGCTCTTTGCGCGGGGAAGCAGCACCAAGTTTCACGGCCAAACGCGTTGGC	240
241	Qy	 ACTAGGGTTCAGAAATGGCTCAACAAGTCCCTGATGGTTGCGCGCAATGCGCTGAAATCCAA	300
241	Db	 ACTAGGGTTCAGAAATGGCTCAACAAGTCCCTGATGGTTGCGCGCAATGGCTGAAATCCAA	300
301	Qy	 GTACTACAGACTTTGTGATAGAGCTGAAGCTTGGGGCAATGCTCTAGAAAAACGGTGGGCCAC	360
301	Db	 GTACTACAGACTTTGTGATAGAGCTGAAGCTTGGGGCAATGCTCTAGAAAAACGGTGGGCCAC	360
361	Qy	 AGCCGGGGTTGTGACCTCGGTGGCCTTTCATGCTCACTCTCCCGATCCTCGTCTCGAAGGT	420
361	Db	 AGCCGGGGTTGTGACCTCGGTGGCCTTTCATGCTCACTCTCCCGATCCTCGTCTCGAAGGT	420
421	Qy	 GCAGGACTCCAAACAGGCGAAAAATGCTCGCTACTCAGTTTCTCTTCCTTCCTCGGTGTGTT	480
421	Db	 GCAGGACTCCAAACAGGCGAAAAATGCTCGCTACTCAGTTTCTCTTCCTTCCTCGGTGTGTT	480
481	Qy	 GGGCATCTTTGGCCTCACTTTGGGATCCCTTTCCATCGGACTGGAACAGGGGCCAC	540
481	Db	 GGGCATCTTTGGCCTCACTTTGGGATCCCTTTCCATCGGACTGGAACAGGGGCCAC	540
541	Qy	 ACGCTTCTTCTCTTTGGGATCCCTTTCCATCGGACTGGAACAGGGGCCAC	600
541	Db	 ACGCTTCTTCTCTTTGGGATCCCTTTCCATCGGACTGGAACAGGGGCCAC	600
601	Qy	 TGTCACTGTGACCAAGCTCGTCCGGGGGAGGAAGCCCTTTCCCTGTTGGTGATTTCTGGG	660
601	Db	 TGTCACTGTGACCAAGCTCGTCCGGGGGAGGAAGCCCTTTCCCTGTTGGTGATTTCTGGG	660
661	Qy	 TCTGGCCGTGGGCTTCAGCCTTAGTCCAGGATGTTATCGTATTGAATATATTGTCTGAC	720
661	Db	 TCTGGCCGTGGGCTTCAGCCTTAGTCCAGGATGTTATCGTATTGAATATATTGTCTGAC	720
721	Qy	 CATGAATAGGACCAACGTCAAATGTCTTTCTGAGCTTTCGCTCTCTGTCGCAATGAAGA	780
721	Db	 CATGAATAGGACCAACGTCAAATGTCTTTCTGAGCTTTCGCTCTCTGTCGCAATGAAGA	780
781	Qy	 CTTTGTCTCTCTGCTCACTACGTGCTCTCTCTGATGCGGTGACCTTCCTCATGTGCTCTC	840
781	Db	 CTTTGTCTCTCTGCTCACTACGTGCTCTCTCTGATGCGGTGACCTTCCTCATGTGCTCTC	840
841	Qy	 CTTCACCTTCTGTGGTTCCTTTCACGGGCTGGAAGAGACATGGGGCCCAACATCTACCTCAC	900
841	Db	 CTTCACCTTCTGTGGTTCCTTTCACGGGCTGGAAGAGACATGGGGCCCAACATCTACCTCAC	900
901	Qy	 GATGCTCTCTCCAAATGCGCATCTGGGTGGCCTGGATCACTGCTCATGCTTCTCTGACTT	960
901	Db	 GATGCTCTCTCCAAATGCGCATCTGGGTGGCCTGGATCACTGCTCATGCTTCTCTGACTT	960
961	Qy	 TGACCGCAGGTGGGATGACACCATCTCAGCTCCGCTTGCTGCTCCCAATGGCTGGGTGTT	1020
961	Db	 TGACCGCAGGTGGGATGACACCATCTCAGCTCCGCTTGCTGCTCCCAATGGCTGGGTGTT	1020
1021	Qy	 CCTGTGTGCTTATGTTAGTCCCGAGTTTGTGCTGCTCAACAGCAACGAAACCCCATGGA	1080
1021	Db	 CCTGTGTGCTTATGTTAGTCCCGAGTTTGTGCTGCTCAACAGCAACGAAACCCCATGGA	1080
1081	Qy	 TTATCTCTGTTGAGGATGCTTCTGTAAACCTCAAACCTCAAACCTCAAACCTCAAACCTCAA	1140
1081	Db	 TTATCTCTGTTGAGGATGCTTCTGTAAACCTCAAACCTCAAACCTCAAACCTCAAACCTCAA	1140
1141	Qy	 GAAACAGGCTTACTCTCAAGAGGAATCACTCAGAGTTTTCAGAGACAGGGGACACGCT	1200
1141	Db	 GAAACAGGCTTACTCTCAAGAGGAATCACTCAGAGTTTTCAGAGACAGGGGACACGCT	1200
1201	Qy	 CTATGCCCCCTATTCCACACATTTTTCAGCTGACGAACAGGCTCTCCCAAGGAATTTCTC	1260
1201	Db	 CTATGCCCCCTATTCCACACATTTTTCAGCTGACGAACAGGCTCTCCCAAGGAATTTCTC	1260
1261	Qy	 CATCCCCACGGGCCCAACGCTTGGCCGAGCCCTTACAAAGACTATGAAGTAAAGAAAGAGGG	1320

Db	1261	CATCCACGGGCCACCGCTTGGCCGAGCCCTTACAAGA	CTATGAAGTAAAGAAAGAGGG	13261
Qy	1321	CAGCTAACTCTGCTCAAGAGTGGGACAAATGCAGCGCGGCGGCAGATCTAGCGGAGC		1380
Db	1321	CAGCTAACTCTGCTCAAGAGTGGGACAAATGCAGCGCGGCGGCAGATCTAGCGGAGC		1380
Qy	1381	TCAAGGGATGTGGGCGAATCTTTGAGTCTTCTGAGAAAAC	CTGTACAAGACACTACGGGA	1440
Db	1381	TCAAGGGATGTGGGCGAATCTTTGAGTCTTCTGAGAAAAC	CTGTACAAGACACTACGGGA	1440
Qy	1441	ACAGTTTGCCTCCCTCCAGCCTCAACCAAA	TTCTTCATGCTGGGGCTGATGTGGGCT	1500
Db	1441	ACAGTTTGCCTCCCTCCAGCCTCAACCAAA	TTCTTCATGCTGGGGCTGATGTGGGCT	1500
Qy	1501	AGTAAGACTCCAGTCTTAGAGCGCTGTAGTAT	TTTTTTTTTTTGTCTCATCTTTGG	1560
Db	1501	AGTAAGACTCCAGTCTTAGAGCGCTGTAGTAT	TTTTTTTTTTTGTCTCATCTTTGG	1560
Qy	1561	ATACTTCTTTAAGTGGGAGTCTCAGGCAACTCAAGTTT	TAGACCCCTTACTCTTTTGTGTTT	1620
Db	1561	ATACTTCTTTAAGTGGGAGTCTCAGGCAACTCAAGTTT	TAGACCCCTTACTCTTTTGTGTTT	1620
Qy	1621	GTTTTTTGAACAGGATCTTGCTCTGTCACCCAGGCTT	GAGTGCAGTGGCGCATCACAG	1680
Db	1621	GTTTTTTGAACAGGATCTTGCTCTGTCACCCAGGCTT	GAGTGCAGTGGCGCATCACAG	1680
Qy	1681	CCCAGTGCAGCCTCGACACCTGTGCTCAAGCAAT	CTCCCATCTCCACTCCCAAAGTG	1740
Db	1681	CCCAGTGCAGCCTCGACACCTGTGCTCAAGCAAT	CTCCCATCTCCACTCCCAAAGTG	1740
Qy	1741	CTGGGATGACAGGGGTGAGCCACAGCTCCAGCT	TAGGCCCTTAATCTTGCTGTTATTTT	1800
Db	1741	CTGGGATGACAGGGGTGAGCCACAGCTCCAGCT	TAGGCCCTTAATCTTGCTGTTATTTT	1800
Qy	1801	CCATGAGCTAAAGTCTGGTCACTCGAGCTCACGCT	TGGCTCACACAGCTCTAGGGGCTG	1860
Db	1801	CCATGAGCTAAAGTCTGGTCACTCGAGCTCACGCT	TGGCTCACACAGCTCTAGGGGCTG	1860
Qy	1861	CTCCTCTAACTCACAGTGGGTTTTGTGAGGCTCT	TGTGGCCAGACAGACCTGCATATCT	1920
Db	1861	CTCCTCTAACTCACAGTGGGTTTTGTGAGGCTCT	TGTGGCCAGACAGACCTGCATATCT	1920
Qy	1921	GAGCAAAATAGCAAAAGCCTCTCTCAGCCCA	CTGGCTGGAATCTACCTGGAAGCCAAC	1980
Db	1921	GAGCAAAATAGCAAAAGCCTCTCTCAGCCCA	CTGGCTGGAATCTACCTGGAAGCCAAC	1980
Qy	1981	TTGCTGGCACCCCGCTCCCAACCTCTTGCTCGGT	TAGGAGAGCTAAAGATCACCC	2040
Db	1981	TTGCTGGCACCCCGCTCCCAACCTCTTGCTCGGT	TAGGAGAGCTAAAGATCACCC	2040
Qy	2041	TAAATTTACTCATCTCTCTAGTGCCTCACAT	TGGGCTCAGCAGCTCCCGACCA	2100
Db	2041	TAAATTTACTCATCTCTCTAGTGCCTCACAT	TGGGCTCAGCAGCTCCCGACCA	2100
Qy	2101	ATTTCAGAGTCAACCCTCTCTCTTGAGATGTCC	CAAACTTGCTGTCAATTCGAGATC	2160
Db	2101	ATTTCAGAGTCAACCCTCTCTCTTGAGATGTCC	CAAACTTGCTGTCAATTCGAGATC	2160
Qy	2161	TAAATCTCCCTTACGCTCGCCAGGAATCTTT	TTCAGACCTCACTAGCAAGCCCGGTG	2220
Db	2161	TAAATCTCCCTTACGCTCGCCAGGAATCTTT	TTCAGACCTCACTAGCAAGCCCGGTG	2220
Qy	2221	CTCCTTGTACGAGAAATTTGTAGATCATTTCT	CACTTCAAAATTCCTGGGCTGATCTTCT	2280
Db	2221	CTCCTTGTACGAGAAATTTGTAGATCATTTCT	CACTTCAAAATTCCTGGGCTGATCTTCT	2280
Qy	2281	CTCATCTTGCAACCCCACTCTGTAAATAGATTA	TCGCAATTTACGGCTGCATCTGTAA	2340
Db	2281	CTCATCTTGCAACCCCACTCTGTAAATAGATTA	TCGCAATTTACGGCTGCATCTGTAA	2340
Qy	2341	GTGGGCAATGTCTCTTAATGGAGGAGTGTTCAT	TGTATTAATAGATTATTCACCTGAGTAT	2400
Db	2341	GTGGGCAATGTCTCTTAATGGAGGAGTGTTCAT	TGTATTAATAGATTATTCACCTGAGTAT	2400

QY 2401 GCATTAAGATGCTGGGCACTCTTTTCATGCTGGTGGCAGCAAAAAA 2456
Db |||||
2401 GCATTAAGATGCTGGGCACTCTTTTCATGCTGGTGGCAGCAAAAAA 2456
Db |||||

RESULT 2
US10-269-909-63
; Sequence 63, Application US/10269909
; Publication No. US20030180747A1
; GENERAL INFORMATION:
; APPLICANT: HRUBAN, RALPH H.
; APPLICANT: ARGANI, PEDRAM
; APPLICANT: IACOBUIO-DONAHUE, CHRISTINE
; APPLICANT: MAITRA, ANIRBAN
; TITLE OF INVENTION: PANCREATIC CANCER DIAGNOSIS AND THERAPIES
; FILE REFERENCE: 59303(71699)
; CURRENT APPLICATION NUMBER: US/10/269,909
; PRIOR FILING DATE: 2003-10-11
; PRIOR APPLICATION NUMBER: 60/328,609
; PRIOR FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 60/332,754
; PRIOR FILING DATE: 2001-11-19
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO: 63
; LENGTH: 2456
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-269-909-63

Query Match 100.0%; Score 2456; DB 7; Length 2456;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2456; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ATAAAGCATGAAGTGGGCACTGGAACTGGTCTCTCCCTCGACCCCTCCCC 60
Db |||||
QY 61 TCCTGTCTCTGCTCACCCTCGCTGCTCTCCCTCGGAGGGCGCTTTATA 120
Db |||||
QY 61 TCCTGTCTCTGCTCACCCTCGCTGCTCTCCCTCGGAGGGCGCTTTATA 120
Db |||||
QY 121 ACAAGTCTCAGAGTGGGCGGGAAGTCTGCTCAAGTCTCCCTCGACCTGAGG 180
Db |||||
QY 121 ACAAGTCTCAGAGTGGGCGGGAAGTCTGCTCAAGTCTCCCTCGACCTGAGG 180
Db |||||
QY 181 CTGCTCTGCTGCTCTTGGCGGGAAGTCTGCTCAAGTCTCCCTCGACCTGAGG 240
Db |||||
QY 181 CTGCTCTGCTGCTCTTGGCGGGAAGTCTGCTCAAGTCTCCCTCGACCTGAGG 240
Db |||||
QY 241 ACTAGGTCAGAAATGCTCAACAGTCTGATGCTGCGCAATGCTGAAATCAA 300
Db |||||
QY 241 ACTAGGTCAGAAATGCTCAACAGTCTGATGCTGCGCAATGCTGAAATCAA 300
Db |||||
QY 301 GTACTACAGATTTGATAGGCTGAGTGGGCAATGCTCTAGAAAGTGGCCAC 360
Db |||||
QY 301 GTACTACAGATTTGATAGGCTGAGTGGGCAATGCTCTAGAAAGTGGCCAC 360
Db |||||
QY 361 AGCGGGGTGTGACCTCGGTGCTCTCATGCTCAGTCTCCGATCTCTGCAAGGT 420
Db |||||
QY 361 AGCGGGGTGTGACCTCGGTGCTCTCATGCTCAGTCTCCGATCTCTGCAAGGT 420
Db |||||
QY 421 GCAGGACTCAACAGGCGAAATGCTGCTCTGCTCTCTCTCTCTCTCTCTCT 480
Db |||||
QY 421 GCAGGACTCAACAGGCGAAATGCTGCTCTGCTCTCTCTCTCTCTCTCTCT 480
Db |||||
QY 481 GGGCATCTTGGGCTCAGCTTGGCTCATCATGCTGAGGAGGAGGAGGAGGAG 540
Db |||||
QY 481 GGGCATCTTGGGCTCAGCTTGGCTCATCATGCTGAGGAGGAGGAGGAGGAG 540
Db |||||
QY 541 ACCCT 600
Db |||||

Db 541 AGCTTTCT 600
QY 601 TGTCACTCTGACCAAGCTCTGTCGGGGAGGAGCCCTTTCTCTCTCTCTCTCT 660
Db 601 TGTCACTCTGACCAAGCTCTGTCGGGGAGGAGCCCTTTCTCTCTCTCTCTCT 660
QY 661 TCTGGCGCTGGGCTTCCAGCTCTGTCAGGATGTTATCGCTATTGAATATATCT 720
Db 661 TCTGGCGCTGGGCTTCCAGCTCTGTCAGGATGTTATCGCTATTGAATATATCT 720
QY 721 CATGAATAGACCAACGTCATCTCTTTCTGAGCTTTTCGCTCTCTCTCTCTCT 780
Db 721 CATGAATAGACCAACGTCATCTCTTTCTGAGCTTTTCGCTCTCTCTCTCTCT 780
QY 781 CTTTGTCT 840
Db 781 CTTTGTCT 840
QY 841 CTTACCT 900
Db 841 CTTACCT 900
QY 901 GATGCT 960
Db 901 GATGCT 960
QY 961 TGACCGCAGGTGGGATGACCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1020
Db 961 TGACCGCAGGTGGGATGACCACTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1020
QY 1021 CTTTGTGGCTTATGTTAGTCCCGGCTTGGCTGCTCACAAGCAACCAACCT 1080
Db 1021 CTTTGTGGCTTATGTTAGTCCCGGCTTGGCTGCTCACAAGCAACCAACCT 1080
QY 1081 TTATCTCTGTTAGGATGCTTTCTGTAACCTCAACTCGTGAAGAGAGCTATG 1140
Db 1081 TTATCTCTGTTAGGATGCTTTCTGTAACCTCAACTCGTGAAGAGAGCTATG 1140
QY 1141 GAACAGGCTCTCTCAAGAGGAAATCACTCAAGGTTTGAAGAGACAGGACAGCT 1200
Db 1141 GAACAGGCTCTCTCAAGAGGAAATCACTCAAGGTTTGAAGAGACAGGACAGCT 1200
QY 1201 CTATGCCCCCTATTTCCACACATTTTCAGCTCTCAAGAACCAAGCTCTCC 1260
Db 1201 CTATGCCCCCTATTTCCACACATTTTCAGCTCTCAAGAACCAAGCTCTCC 1260
QY 1261 CATCCCAAGGCGCCACGCTTGGCGGAGCCTTACAAAGCTATGAAGTAAAG 1320
Db 1261 CATCCCAAGGCGCCACGCTTGGCGGAGCCTTACAAAGCTATGAAGTAAAG 1320
QY 1321 CAGCTAACTCTGCTCTGAAGAGTGGGACAAATGACAGCGCGGCGGAGATC 1380
Db 1321 CAGCTAACTCTGCTCTGAAGAGTGGGACAAATGACAGCGCGGCGGAGATC 1380
QY 1381 TCAAGGGGATGTTGGGGAATCTTGAAGTCTCTGAGAAACTGTAAGAACTAC 1440
Db 1381 TCAAGGGGATGTTGGGGAATCTTGAAGTCTCTGAGAAACTGTAAGAACTAC 1440
QY 1441 ACAGTTTGGCTCTCTCTCCAGCTCTCAACCAATTTCTTCCATGCTGGGCT 1500
Db 1441 ACAGTTTGGCTCTCTCTCCAGCTCTCAACCAATTTCTTCCATGCTGGGCT 1500
QY 1501 AGTAAGACTCCAGTCTTGAAGCGCTGAGTATTTTTTTTTTTTTTTTTTTT 1560
Db 1501 AGTAAGACTCCAGTCTTGAAGCGCTGAGTATTTTTTTTTTTTTTTTTTTT 1560
QY 1561 ATACTCTTTTAAAGTGGGAGTCTCAGGCAACTCAAGTTTAGACCTTACTCT 1620
Db 1561 ATACTCTTTTAAAGTGGGAGTCTCAGGCAACTCAAGTTTAGACCTTACTCT 1620
QY 1621 GTTTTTTGAACAGGATCTTGTCTGTCAACCGGCTTGAAGTGTGAGTGTGAT 1680
Db 1621 GTTTTTTGAACAGGATCTTGTCTGTCAACCGGCTTGAAGTGTGAGTGTGAT 1680

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: June 8, 2006, 10:32:39 ; Search time 50 seconds
(without alignments)
624.969 Million cell updates/sec

Title: US-10-600-816-3

Perfect score: 1865

Sequence: 1 MATTVPDGRNGLSKYRL.....PRAHWPSPYKDYEVKES 357

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 650591 seqs, 87530628 residues

Total number of hits satisfying chosen parameters: 650591

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA:*

- 1: /EMC_Celerra_SIDS3/ptodata/2/iaa/5 COMB.pcp.*
- 2: /EMC_Celerra_SIDS3/ptodata/2/iaa/6 COMB.pcp.*
- 3: /EMC_Celerra_SIDS3/ptodata/2/iaa/7 COMB.pcp.*
- 4: /EMC_Celerra_SIDS3/ptodata/2/iaa/H COMB.pcp.*
- 5: /EMC_Celerra_SIDS3/ptodata/2/iaa/FCRUS COMB.pcp.*
- 6: /EMC_Celerra_SIDS3/ptodata/2/iaa/RE COMB.pcp.*
- 7: /EMC_Celerra_SIDS3/ptodata/2/iaa/backfiles1.pcp.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	1865	100.0	357	2	US-09-949-016-6443	Sequence 6443, Ap
2	1865	100.0	390	2	US-09-949-016-9484	Sequence 9484, Ap
3	1782	95.5	347	2	US-09-188-930-326	Sequence 326, App
4	1782	95.5	347	2	US-09-312-283C-326	Sequence 326, App
5	350	18.8	68	2	US-09-188-930-123	Sequence 123, App
6	350	18.8	68	2	US-09-312-283C-123	Sequence 123, App
7	157.5	8.4	256	2	US-09-964-956-85	Sequence 85, Appl
8	146.5	7.9	879	2	US-09-964-956-53	Sequence 53, Appl
9	146.5	7.9	879	2	US-09-964-956-54	Sequence 54, Appl
10	145.5	7.8	879	2	US-09-964-956-17	Sequence 17, Appl
11	140.5	7.5	879	2	US-09-964-956-52	Sequence 52, Appl
12	139.5	7.5	879	1	US-08-072-574-6	Sequence 6, Appli
13	139.5	7.5	879	1	US-08-486-270-6	Sequence 6, Appli
14	139.5	7.5	879	2	US-08-367-264-6	Sequence 6, Appli
15	139.5	7.5	879	2	US-08-794-158-2	Sequence 2, Appli
16	139.5	7.5	879	2	US-09-153-757-6	Sequence 6, Appli
17	139.5	7.5	879	2	US-09-459-715-6	Sequence 6, Appli
18	136	7.3	200	2	US-09-205-258-349	Sequence 349, App
19	136	7.3	200	2	US-10-004-860-349	Sequence 349, App
20	131.5	7.1	872	2	US-08-337-797A-2	Sequence 2, Appli
21	131.5	7.1	872	2	US-09-258-523-2	Sequence 2, Appli
22	131	7.0	877	2	US-09-619-353-2	Sequence 2, Appli
23	124	6.6	863	2	US-09-619-353-14	Sequence 14, Appl
24	119.5	6.4	1078	2	US-10-125-772-28	Sequence 28, Appl
25	119.5	6.4	1078	2	US-10-125-772-28	Sequence 28, Appl
26	119.5	6.4	1078	2	US-10-125-792-28	Sequence 28, Appl

27	116.5	6.2	856	2	US-09-619-353-8	Sequence 8, Appli
28	116	6.2	1085	1	US-08-485-588-5	Sequence 5, Appli
29	116	6.2	1085	1	US-08-484-565-5	Sequence 5, Appli
30	116	6.2	1085	1	US-08-480-751-5	Sequence 5, Appli
31	116	6.2	1085	1	US-08-943-986-5	Sequence 5, Appli
32	116	6.2	1085	2	US-08-353-784-5	Sequence 5, Appli
33	116	6.2	1085	2	US-08-484-719B-5	Sequence 5, Appli
34	116	6.2	1085	2	US-08-484-159-5	Sequence 5, Appli
35	115.5	6.2	835	2	US-09-619-353-7	Sequence 7, Appli
36	115.5	6.2	1027	2	US-09-162-021B-2	Sequence 2, Appli
37	115.5	6.2	1027	2	US-10-268-051-8	Sequence 8, Appli
38	115.5	6.2	1027	2	US-10-125-772-2	Sequence 2, Appli
39	115.5	6.2	1027	2	US-10-125-778-2	Sequence 2, Appli
40	115.5	6.2	1027	2	US-10-125-792-2	Sequence 2, Appli
41	113.5	6.1	854	2	US-09-619-353-10	Sequence 10, Appli
42	113	6.1	388	2	US-10-125-772-6	Sequence 6, Appli
43	113	6.1	388	2	US-10-125-778-6	Sequence 6, Appli
44	113	6.1	388	2	US-10-125-792-6	Sequence 6, Appli
45	113	6.1	850	2	US-10-125-772-12	Sequence 12, Appli

ALIGNMENTS

RESULT 1

US-09-949-016-6443
; Sequence 6443, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6443
; LENGTH: 357
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-6443

Query Match 100.0%; Score 1865; DB 2; Length 357;
Best Local Similarity 100.0%; Pred. No. 3.2e-194;
Matches 357; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	MATTVPDGRNGLSKYRLCDKAEAWGIVLETVATAGVVTSVAFMLTLPILVCKVQDSN	60
Db	1	MATTVPDGRNGLSKYRLCDKAEAWGIVLETVATAGVVTSVAFMLTLPILVCKVQDSN	60
Qy	61	RRKMLPTQFLFLLGVGLFGLTFAPFIIGLDGSTGTTRFPLFGILFISICFSCLLAHAVSLT	120
Db	61	RRKMLPTQFLFLLGVGLFGLTFAPFIIGLDGSTGTTRFPLFGILFISICFSCLLAHAVSLT	120
Qy	121	KLVRGRKPLSLIIVILGLAVGFSLVQDVIAEIVILTMRTNVTNVSSELSAPRNEDFVLL	180
Db	121	KLVRGRKPLSLIIVILGLAVGFSLVQDVIAEIVILTMRTNVTNVSSELSAPRNEDFVLL	180
Qy	181	LTIVFLMALTFMSSFTFCGSFTGCKRHGAHIYLTMLLSIAIWAWITLLMLPDFDRRW	240
Db	181	LTIVFLMALTFMSSFTFCGSFTGCKRHGAHIYLTMLLSIAIWAWITLLMLPDFDRRW	240
Qy	241	DDTILSSALAANGWVFLAYVSPFWLTKQRNPMDPVEDAFCKPQLVKKSIGVENRAY	300
Db	241	DDTILSSALAANGWVFLAYVSPFWLTKQRNPMDPVEDAFCKPQLVKKSIGVENRAY	300

```
QY 301 SQBEITQGFETGDTLYAPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 357
Db 301 SQBEITQGFETGDTLYAPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 357

RESULT 2
US-09-949-016-9484
; Sequence 9484, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9484
; LENGTH: 390
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-9484

Query Match 100.0%; Score 1865; DB 2; Length 390;
Best Local Similarity 100.0%; Pred. No. 3.7e-194;
Matches 357; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MATTPDGCNGLKSKYRLCDKAEAGIVLETATAGVVTSAFMLTLPILVCKVQDSN 60
Db 34 MATTPDGCNGLKSKYRLCDKAEAGIVLETATAGVVTSAFMLTLPILVCKVQDSN 93

QY 61 RRKMLPTQFLGLGVIGLTFAGIIGDSTGTRFFLFGILFSCISCLLAHAVSLT 120
Db 94 RRKMLPTQFLGLGVIGLTFAGIIGDSTGTRFFLFGILFSCISCLLAHAVSLT 153

QY 121 KLVGRKPLSLAVILGLAVGSLVDVIAEYIVLTMTNTNVNVSFSELSAPRNEDFVLL 180
Db 154 KLVGRKPLSLAVILGLAVGSLVDVIAEYIVLTMTNTNVNVSFSELSAPRNEDFVLL 213

QY 181 LTVLFLMALTFMSFTFCGSGFTGKRGHAIYLTMLLSIAIWAIVTLLMLPDFDRW 240
Db 214 LTVLFLMALTFMSFTFCGSGFTGKRGHAIYLTMLLSIAIWAIVTLLMLPDFDRW 273

QY 241 DDTILSSALAANGWVLLAYVSEFVLLTKQRPMDYPVEDAFCKPOLVKSYGVENRAY 300
Db 274 DDTILSSALAANGWVLLAYVSEFVLLTKQRPMDYPVEDAFCKPOLVKSYGVENRAY 333

QY 301 SQBEITQGFETGDTLYAPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 357
Db 334 SQBEITQGFETGDTLYAPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 390

RESULT 3
US-09-188-930-326
; Sequence 326, Application US/09188930A
; Patent No. 6150502
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James Greg
; TITLE OF INVENTION: Compositions Isolated From Skin Cells
; FILE REFERENCE: 11000.1011c1
; CURRENT APPLICATION NUMBER: US/09/188,930A

QY 301 SQBEITQGFETGDTLYAPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 357
Db 301 SQBEITQGFETGDTLYAPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 357

Query Match 95.5%; Score 1782; DB 2; Length 347;
Best Local Similarity 99.1%; Pred. No. 3.3e-185;
Matches 341; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 14 KSKYRLCDKAEAGIVLETATAGVVTSAFMLTLPILVCKVQDSNRKMLPTQFLFL 73
Db 4 RPRYRLCDKAEAGIVLETATAGVVTSAFMLTLPILVCKVQDSNRKMLPTQFLFL 63

QY 74 GVLGIFGLTFAGIIGDSTGTRFFLFGILFSCISCLLAHAVSLTKLVGRKPLSLV 133
Db 64 GVLGIFGLTFAGIIGDSTGTRFFLFGILFSCISCLLAHAVSLTKLVGRKPLSLV 123

QY 134 ILGLAVGSLVDVIAEYIVLTMTNTNVNVSFSELSAPRNEDFVLLTYVLFMALTF 193
Db 124 ILGLAVGSLVDVIAEYIVLTMTNTNVNVSFSELSAPRNEDFVLLTYVLFMALTF 183

QY 194 MSSFTFCGSGFTGKRGHAIYLTMLLSIAIWAIVTLLMLPDFDRWDDTILSSALA 253
Db 184 MSSFTFCGSGFTGKRGHAIYLTMLLSIAIWAIVTLLMLPDFDRWDDTILSSALA 243

QY 254 WYFLLAYVSEFVLLTKQRPMDYPVEDAFCKPOLVKSYGVENRAYSOBEITQGFETG 313
Db 244 WYFLLAYVSEFVLLTKQRPMDYPVEDAFCKPOLVKSYGVENRAYSOBEITQGFETG 303

QY 314 DTLYPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 357
Db 304 DTLYPYSTHFOLOQNOPPOKEFSIPRAHAWPSYKDYEVKKEGS 347

Query Match 95.5%; Score 1782; DB 2; Length 347;
Best Local Similarity 99.1%; Pred. No. 3.3e-185;
Matches 341; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 14 KSKYRLCDKAEAGIVLETATAGVVTSAFMLTLPILVCKVQDSNRKMLPTQFLFL 73
Db 4 RPRYRLCDKAEAGIVLETATAGVVTSAFMLTLPILVCKVQDSNRKMLPTQFLFL 63

QY 74 GVLGIFGLTFAGIIGDSTGTRFFLFGILFSCISCLLAHAVSLTKLVGRKPLSLV 133
Db 64 GVLGIFGLTFAGIIGDSTGTRFFLFGILFSCISCLLAHAVSLTKLVGRKPLSLV 123
```

XX DE Human cancer related protein SEQ ID NO:226.
XX KW Human; cancer; diagnosis; screening; modulator; leukaemia; ischaemia;
XX KW heart disease; atherosclerosis; endometriosis.
XX OS Homo sapiens.
XX PN WD2003025138-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-US029560.
XX PR 17-SEP-2001; 2001US-0323469P.
XX PR 20-SEP-2001; 2001US-0323887P.
XX PR 13-NOV-2001; 2001US-0350666P.
XX PR 08-FEB-2002; 2002US-0355145P.
XX PR 08-FEB-2002; 2002US-0355257P.
XX PR 12-APR-2002; 2002US-0372246P.
XX PA (EOSB-) EOS\BIOTECHNOLOGY INC.
XX PI Afar D, Aziz N, Gish KC, Hevezi PA, Mack DH, Wilson KE;
XX PI Zlotnik A;
XX XX
XX DR WPI; 2003-354600/33.
XX DR N-PSDB; ACC72695.
XX XX
XX PT New genes that are up-regulated or down-regulated in cancers, useful as
XX PT markers for diagnosing e.g. cancer, ischemia or heart diseases, or as
XX PT therapeutic targets for screening drugs for treating these diseases.
XX XX
XX PS Claim 12; Page 740; 767pp; English.
XX XX
XX CC The present invention describes an isolated nucleic acid molecule, which
XX CC comprises the sequence of any of the genes that are up-regulated or down-
XX CC regulated in specific cancers (e.g. about 1031 genes up-regulated in
XX CC acute lymphocytic leukemia). ACC72641 to ACC72860 represent cancer
XX CC related gene nucleotide sequences which encode the proteins given in
XX CC ABR58521 to ABR58709. Also described: (1) determining the presence or
XX CC absence of a pathological cell in a patient; (2) an expression vector
XX CC comprising a nucleic acid molecule described above; (3) a host cell
XX CC comprising the vector; (4) an isolated polypeptide, which is encoded by
XX CC the nucleic acid; (5) an antibody that specifically binds the polypeptide
XX CC of (4); (6) specifically targeting a compound to a pathological cell in a
XX CC patient by administering to the patient the antibody above; and (7) a
XX CC drug screening assay. The nucleic acid is useful as diagnostic markers or
XX CC therapeutic targets. In particular, the nucleic acid is useful for
XX CC diagnosing a pathology, e.g. cancer (e.g. cancer of the bone marrow,
XX CC bladder, brain, breast, cervix, colon/rectum, kidney, lung, ovary,
XX CC pancreas, prostate, skin and uterus), wounds, ischaemia, heart diseases,
XX CC atherosclerosis and endometriosis. The nucleic acid is also useful in
XX CC drug screening, particularly for identifying agents for treating these
XX CC pathologies
XX XX
XX SQ Sequence 357 AA;
Query Match 100.0%; Score 1865; DB 6; Length 357;
Best Local Similarity 100.0%; Pred. No. 2.7e-203;
Matches 357; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MATTPDGCGRGLKSKYIRLCDKAEANGIVLETVATAGVTVTSVAFMLTLPIILCKVQDSN 60
DB 1 MATTPDGCGRGLKSKYIRLCDKAEANGIVLETVATAGVTVTSVAFMLTLPIILCKVQDSN 60
QY 61 RRKMLPTQFLGLVGLGIFGLTFAFIIGLDGSGTPTFFLFGILFSLFCPSCLLAHAVSLT 120
DB 61 RRKMLPTQFLGLVGLGIFGLTFAFIIGLDGSGTPTFFLFGILFSLFCPSCLLAHAVSLT 120
QY 121 KLVRGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEFDVLL 180
DB 121 KLVRGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEFDVLL 180

181 LTIVLFLMALTFILMSSFTFCGSGTGWKRHGAHYLTMLLSIAIWMVAMITLMLPDRRW 240
181 LTIVLFLMALTFILMSSFTFCGSGTGWKRHGAHYLTMLLSIAIWMVAMITLMLPDRRW 240
241 DDTILSSALAANGWVFLAYVSPFEFLLTKORNPMDYPVEDAFCKPQLVKKSYGVENRAY 300
241 DDTILSSALAANGWVFLAYVSPFEFLLTKORNPMDYPVEDAFCKPQLVKKSYGVENRAY 300
301 SOEITQGFETGRTLYAPYSTHFOQNQPOKFEFSIPRAHAWPSPYKDYEVKKEGS 357
301 SOEITQGFETGRTLYAPYSTHFOQNQPOKFEFSIPRAHAWPSPYKDYEVKKEGS 357

RESULT 4
ABJ37054
ID ABJ37054 standard; protein; 357 AA.
XX AC ABJ37054;
XX AC
XX 01-MAY-2003 (first entry)
XX DE Human breast cancer / ovarian cancer related protein #30.
XX KW Human; cytostatic; breast cancer; ovarian cancer.
XX OS Homo sapiens.
XX PN WO2003000012-A2.
XX PD 03-JAN-2003.
XX PF 21-JUN-2002; 2002WO-US019773.
XX PR 21-JUN-2001; 2001US-0300159P.
XX PR 27-JUN-2001; 2001US-0301351P.
XX PA (MILL-) MILLENNIUM PHARM INC.
XX PI Veiby OP;
XX WPI; 2003-267848/26.
XX N-PSDB; ABT31923.
XX PT Determining the presence of breast cancer in an individual, involves
XX PT using specific polynucleotide markers.
XX XX
XX PS Disclosure; Page 163-164; 233pp; English.
XX CC The invention comprises a method for assessing whether a patient is
XX CC afflicted with breast cancer or ovarian cancer. The method involves the
XX CC use of specific DNA markers. The method of the invention is useful in the
XX CC detection and treatment of ovarian and breast cancer. Amino acid
XX CC sequences ABJ37025 - ABJ37080 represent human breast/ovarian cancer-
XX CC related proteins
XX XX
XX SQ Sequence 357 AA;
Query Match 100.0%; Score 1865; DB 6; Length 357;
Best Local Similarity 100.0%; Pred. No. 2.7e-203;
Matches 357; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MATTPDGCGRGLKSKYIRLCDKAEANGIVLETVATAGVTVTSVAFMLTLPIILCKVQDSN 60
DB 1 MATTPDGCGRGLKSKYIRLCDKAEANGIVLETVATAGVTVTSVAFMLTLPIILCKVQDSN 60
QY 61 RRKMLPTQFLGLVGLGIFGLTFAFIIGLDGSGTPTFFLFGILFSLFCPSCLLAHAVSLT 120
DB 61 RRKMLPTQFLGLVGLGIFGLTFAFIIGLDGSGTPTFFLFGILFSLFCPSCLLAHAVSLT 120
QY 121 KLVRGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEFDVLL 180
DB 121 KLVRGRKPLSLVILGLAVGFSLVQDVIAIEYIVLTMTNRTNNVNFSELSAPRNEFDVLL 180

i. 2, US 2003/068636 A1, Apr. 10, 2003

QY 181 LTVVFLMALTFLLMSSFTFCGSGTWKRGHAIYLTMLLSIAIWAWITLLMLPDPDRRW 240
Db 181 LTVVFLMALTFLLMSSFTFCGSGTWKRGHAIYLTMLLSIAIWAWITLLMLPDPDRRW 240
QY 241 DDTILSSALAANGWVFLAYVSEFWLLTKQRNPMDPVEDAFCKPOLVKSYGVENRAY 300
Db 241 DDTILSSALAANGWVFLAYVSEFWLLTKQRNPMDPVEDAFCKPOLVKSYGVENRAY 300
QY 301 SQEETIQGFEETGDTLYAPYSTHFLQNPQPOKEFSIPRAHAWPSPYKDYEVKKEGS 357
Db 301 SQEETIQGFEETGDTLYAPYSTHFLQNPQPOKEFSIPRAHAWPSPYKDYEVKKEGS 357
RESULT 5
ABR42649
ID ABR42649 standard; protein; 357 AA.
XX ABR42649;
AC
DT 26-AUG-2003 (first entry)
XX
DE Human GPCR-like retinoic acid-induced gene 1 protein.
XX
KW Human; retinoic acid-induced gene 1; RAIG1; feeding; fasting; GPCR;
KW receptor; G-protein coupled receptor; anorectic; antidiabetic;
KW antidepressant; immunomodulator; transgenic; gene therapy.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Modified-site 4..8
FT /note= "phosphorylated by casein kinase II"
FT Modified-site 8..14
FT /note= "N-myristoylated"
FT Modified-site 38..43
FT /note= "N-myristoylated"
FT Modified-site 59..61
FT /note= "phosphorylated by protein kinase C"
FT Modified-site 80..86
FT /note= "N-myristoylated"
FT Modified-site 88..93
FT /note= "N-myristoylated"
FT Modified-site 102..107
FT /note= "N-myristoylated"
FT Modified-site 124..127
FT /note= "Amidated"
FT Modified-site 136..142
FT /note= "N-myristoylated"
FT Modified-site 158..161
FT /note= "N-glycosylated"
FT Modified-site 201..206
FT /note= "N-myristoylated"
FT Modified-site 301..304
FT /note= "phosphorylated by casein kinase II"
XX
PN WO2003016553-A2.
XX
XX
PD 27-FEB-2003.
XX
XX 20-AUG-2002; 2002WO-US026510.
XX
XX 20-AUG-2001; 2001US-0313940P.
XX
XX (GETH) GENENTECH INC.
PA (CURA-) CURAGEN CORP.
XX
XX Lewin DA, Stewart TA;
XX
DR WPI; 2003-278580/27.
DR N-PSDB; ACC58386.
XX
XX New G-protein coupled receptor-like retinoic acid induced gene 1 (GPCR-

PT like RAIG1) polypeptide and gene, useful for diagnosing or treating
PT metabolic disorders, e.g. obesity, anorexia, cachexia or diabetes.
XX
PS Disclosure; Page 19-20; 150pp; English.
XX
CC The present sequence is that of human G-protein coupled receptor-like
CC retinoic acid induced gene 1 (GPCR-like RAIG1) protein. This is the human
CC homologue of murine GPCR-like RAIG1 (see ABR42648). The murine GPCR-like
CC RAIG1 gene was shown to be differentially regulated during fasting-
CC feeding cycles, with moderate induction early in fasting, down-regulation
CC with extended fasting and 4-fold up-regulation with feeding in recovery
CC from fasting. The differentially expressed gene, its mRNA, and the
CC encoded protein, can each be manipulated to detect and treat metabolic
CC disorders associated with up- or down-regulation of GPCR-like RAIG1
CC activity, such as obesity, anorexia, cachexia or diabetes
XX
SQ Sequence 357 AA;
Query Match 100.0%; Score 1865; DB 6; Length 357;
Best Local Similarity 100.0%; Pred. No. 2.7e-203;
Matches 357; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MATTPDGCGRGLKSKYYRLCDKAEAWGIVLETATAGVTVTSVAFMLTLPILVCKVQDSN 60
Db 1 MATTPDGCGRGLKSKYYRLCDKAEAWGIVLETATAGVTVTSVAFMLTLPILVCKVQDSN 60
QY 61 RRKMLPTQFLFLLGVLFGLTLPFTIIGDGGTGTPTFFLFGILFCISCLLAHAVSLT 120
Db 61 RRKMLPTQFLFLLGVLFGLTLPFTIIGDGGTGTPTFFLFGILFCISCLLAHAVSLT 120
QY 121 KLVGRKPNASLLVILGLAVGFSLVQDVIAIEIVLTMTNTNVNVSFELSAPRNEDFVLL 180
Db 121 KLVGRKPNASLLVILGLAVGFSLVQDVIAIEIVLTMTNTNVNVSFELSAPRNEDFVLL 180
QY 181 LTYVFLMALTFLLMSSFTFCGSGTWKRGHAIYLTMLLSIAIWAWITLLMLPDPDRRW 240
Db 181 LTYVFLMALTFLLMSSFTFCGSGTWKRGHAIYLTMLLSIAIWAWITLLMLPDPDRRW 240
QY 241 DDTILSSALAANGWVFLAYVSEFWLLTKQRNPMDPVEDAFCKPOLVKSYGVENRAY 300
Db 241 DDTILSSALAANGWVFLAYVSEFWLLTKQRNPMDPVEDAFCKPOLVKSYGVENRAY 300
QY 301 SQEETIQGFEETGDTLYAPYSTHFLQNPQPOKEFSIPRAHAWPSPYKDYEVKKEGS 357
Db 301 SQEETIQGFEETGDTLYAPYSTHFLQNPQPOKEFSIPRAHAWPSPYKDYEVKKEGS 357
RESULT 6
ABP81984
ID ABP81984 standard; protein; 357 AA.
XX
XX ABP81984;
AC
XX
DT 04-MAR-2003 (first entry)
XX
XX Human G protein-coupled receptor RAIG1 protein SEQ ID NO:454.
XX
XX G protein-coupled receptor; GPCR; antigenic peptide; gene therapy;
KW G protein-coupled receptor modulator; antibody; immune-related disease;
KW growth-related disease; cell regeneration-related disease; AIDS; cancer;
KW immunological-related cell proliferative disease; autoimmune disease;
KW Alzheimer's disease; atherosclerosis; infection; osteoarthritis; allergy;
KW osteoporosis; cardiomyopathy; inflammation; Crohn's disease; diabetes;
KW graft versus host disease; Parkinson's disease; multiple sclerosis; pain;
KW psoriasis; anxiety; depression; schizophrenia; dementia; memory loss;
KW mental retardation; epilepsy; asthma; tuberculosis; obesity; nausea;
KW hypertension; hypotension; renal disorder; rheumatoid arthritis; trauma;
XX
XX Homo sapiens.
XX
XX WO200261087-A2.
XX